CTLA4 overexpression	Soft Tissue Sarcoma	CTLA4 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
CTLA4 overexpression	Mantle Cell Lymphoma	CTLA4 overexpression	Mantle Cell Lymphoma	ibrutinib + rituximab Sensitive: C3 – Early Trials ibrutinib + rituximab Sensitive : C3	ibrutinib + rituximab Sensitive: C3 – Early Trials ibrutinib + rituximab Sensitive : C3
CTLA4 expression	Non Small Cell Lung Cancer	CTLA4 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
CTLA4 promoter hypomethylation	Clear Cell Renal Cell Carcinoma	CTLA4 promoter hypomethylation	Clear Cell Renal Cell Carcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
CTLA4 overexpression	Triple Negative Breast Cancer	CTLA4 overexpression	Triple Negative Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTLA4 underexpression	Urothelial Cancer	CTLA4 underexpression	Urothelial Cancer	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3
CTLA4 expression	Cutaneous Melanoma	CTLA4 expression	Cutaneous Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3
CTLA4 overexpression	Triple Negative Breast Cancer	CTLA4 overexpression	Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: C3 – Early Trials carboplatin + docetaxel Sensitive : C3	carboplatin + docetaxel Sensitive: C3 – Early Trials carboplatin + docetaxel Sensitive : C3
CTLA4 promoter hypomethylation	Squamous Cell Carcinoma of Head and Neck	CTLA4 promoter hypomethylation	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTLA4 overexpression	Melanoma	CTLA4 overexpression	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

Associations(14)

Associations
(14)